FDA Authorizes Abbott's First Dual Glucose-Ketone Sensor for Diabetes
ABT sits 41% above its 52-week low of $81.97 on light trading volume (0.4× avg).
Summary
Abbott received FDA authorization for Libre Duo 10 Day, the world's first dual glucose-ketone sensing technology. The device continuously monitors both glucose and ketones, alerting users to rising ketone levels that can lead to diabetic ketoacidosis (DKA). This is a significant expansion of Abbott's diabetes care portfolio, which already serves over 8 million Libre users globally. The company plans a U.S. launch later this year and is working with major insulin pump makers for integration. This follows Abbott's recent Q2 beat and raised guidance, reinforcing its growth in diabetes care.
At the time of this announcement, ABT was trading at $115.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $200.6B. The 52-week trading range was $81.97 to $137.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.